# About CJC-1295 Prescribed: An Editorial Platform Overview

> CJC-1295 Prescribed is an independent editorial project that publishes summaries of the peer-reviewed CJC-1295 research literature. Not a clinic, not a vendor, not a prescriber.

*What this site is. What it is not. Why the 'prescribed' modifier in the domain reads as specification, not authorization.*

## What this site is

CJC-1295 Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. The site organizes the indexed phase-1 record — primarily Teichman 2006 and follow-on pharmacokinetic, proteomic, and preclinical work — alongside the regulatory file (the FDA 2023 503A Pharmacy Compounding Advisory Committee briefing) and the WADA Prohibited List entry, and presents the record as a feature-by-feature platform overview. We are not a clinic. We do not employ clinicians. We do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

## On the domain name

The 'prescribed' modifier in cjc1295prescribed.com is intended in its older sense — *set out as a specification* — rather than its commercial sense of authorization for use. CJC-1295 is not FDA-approved for any indication, and this site does not describe a prescribing relationship, recommend a course of treatment, or refer readers to clinicians who would. The modifier is editorial framing — a position the publisher occupies relative to the literature. What is *prescribed* here is the structure of the overview: thirty residues, four substitutions, one optional linker, a half-life that runs in days or in minutes depending on which variant the literature is discussing. The site reads as a specification sheet for the research record, not as a recommendation.

## Editorial method

Every quantitative claim on every page traces back to a numbered citation in the references index. Phase-1 dose ranges, half-life figures, IGF-1 fold-change values, proteomic shifts, and the regulatory timeline are each anchored to a specific published paper, FDA document, or WADA entry. Where the indexed literature is silent — long-term human safety, fertility data, hair-related endpoints — the site says so explicitly rather than implying coverage by omission. The platform-overview register (feature cards, comparison tables, spec chips) is a presentational choice; it is not a claim that the compound is itself an approved platform or product.

## What this site is not

Not a clinic. Not a pharmacy. Not a vendor. Not a prescriber. We do not provide medical advice and we do not facilitate access to CJC-1295. We do not have a clinical team, doctors on staff, or pharmacists. The compound is not FDA-approved for any indication and is prohibited under the WADA Code at all times in and out of competition for athletes subject to that code.

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 https://academic.oup.com/jcem/article/91/3/799/2843281
[12] World Anti-Doping Agency. World Anti-Doping Code International Standard — Prohibited List 2025. WADA-AMA. https://www.wada-ama.org/en/prohibited-list
[13] U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting — CJC-1295 bulk drug substance nomination. 2023. https://www.fda.gov/media/183819/download

---

The CJC-1295 research record, set out as a specification — not a clinic, not a vendor, not a prescription.